Immunotherapy for castration-resistant prostate cancer: Has its time arrived? Journal Article

Author: Slovin, S. F.
Article Title: Immunotherapy for castration-resistant prostate cancer: Has its time arrived?
Abstract: Introduction: Within the last decade, multiple innovative immune platforms have been developed and tested in patients with metastatic castration-resistant prostate cancer (mCRPC) with only one demonstrating a survival benefit. The advent of immunogenomics along with the availability of diverse checkpoint inhibitors provides inroads in treating these patients, in many cases with significant clinical impact but unfortunately not in all patients. How to exploit these novel platforms remains an area of increased interest especially in the setting of new agents that can affect the tumor microenvironment and potentially render a ‘cold’ tumor to become ‘hot.’ Areas covered: This review highlights the current changes and challenges in this field and how to best use our current knowledge for better trial designs in patients with mCRPC. Expert opinion: Recent understanding of the inhibitory milieu within the tumor microenvironment has fostered the use of combinatorial strategies that target not only tumor cells but capitalize on controlling inhibitory cell populations and cytokines that induce a hostile setting for immune cells. Immunogenomics and genomic interrogation of prostate cancers have opened a vista as to how patients’ tumors that can respond to immune agents that previously were thought have minimal antitumor activity. © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.
Keywords: review; nonhuman; cancer immunotherapy; prostate cancer; immunotherapy; castration resistant prostate cancer; tumor microenvironment; microbiome; human; male; car t cells; immunogenomics; chimeric antigen receptor t-cell immunotherapy; bites
Journal Title: Expert Opinion on Biological Therapy
Volume: 20
Issue: 5
ISSN: 1471-2598
Publisher: Taylor & Francis Group  
Date Published: 2020-01-01
Start Page: 481
End Page: 487
Language: English
DOI: 10.1080/14712598.2020.1735345
PUBMED: 32097050
PROVIDER: scopus
Notes: Review -- Source: Scopus
Citation Impact
MSK Authors
  1. Susan Slovin
    212 Slovin